Legend Biotech Corporation.
LEGN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Legend Biotech Corporation is a global biotechnology company dedicated to developing, manufacturing, and commercializing novel cell therapies for oncology and other indications. The company focuses on chimeric antigen receptor T-cell (CAR-T) therapies, with a lead product candidate targeting multipl...Show More
Better Health for All
-40
Legend Biotech's core product, CARVYKTI®, treats relapsed or refractory multiple myeloma, an incurable blood cancer, and has the potential to transform treatment.
1
However, the product is associated with a high incidence of severe adverse events. In clinical studies (N=285), 84% of patients experienced Cytokine Release Syndrome (4% Grade ≥3), 57% experienced infections (24% Grade ≥3, 5% Grade 5), and 62% experienced prolonged cytopenias.
2
Neurologic toxicities occurred in 24% of patients (7% Grade ≥3), including fatal or life-threatening cases of Parkinsonism and Guillain-Barré syndrome.
3
Secondary hematological malignancies occurred in 5% of patients.
4
In one trial, there was a numerically higher percentage of early deaths in the CARVYKTI® arm (14%) compared to the control arm (12%).
5
The product's label includes a boxed warning detailing these severe risks, demonstrating comprehensive risk transparency.
6
The company's R&D expenses were $101.9 million for Q1 2025.
7
The company recommends screening for viral infections and administering prophylactic antimicrobials.
8
During the CARTITUDE-1 & -4 studies, 2.5% of Grade 5 infections were due to COVID-19.
9
Neurologic toxicity with parkinsonism, including cognitive impairment and personality changes, has been reported.
10
Fair Money & Economic Opportunity
0
Legend Biotech Corporation is a biotechnology company focused on developing and manufacturing cell therapies, not a financial institution. Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to the company's operations.
1
Fair Pay & Worker Respect
10
Legend Biotech's 2024 ESG Report indicates an employee engagement score of 75%.
1
The same report does not mention any fines or violations related to regulatory actions or compliance issues.
2
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While articles mention a Supplier Code of Conduct and a commitment to ethical conduct,
1
they do not provide quantitative evidence regarding fair-trade certifications, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, the percentage of supplier contracts with enforceable ethical clauses, the share of high-risk materials, or supplier diversity spend.
2
Therefore, all KPIs for this value are omitted due to lack of specific evidence.
Honest & Fair Business
-30
Legend Biotech provides a 24/7 confidential 'Speak Up!' Hotline, operated by NAVEX's EthicsPoint, for anonymous reporting of suspected violations, and retaliation against whistleblowers is prohibited.
1
The company commits to ongoing employee education and annual compliance training on compliance matters.
2
As of March 11, 2025, 70% of the board members are independent.
3
The company has a Global Anti-Corruption Compliance Policy and a Code of Conduct, with training for all new employees and annual refresher sessions.
4
ESG reporting is aligned with SASB and GRI standards, and the company engages third-party experts on ESG initiatives.
5
An independent audit firm performed a cybersecurity program measure in 2024, and animal research facilities are AAALAC-certified, with the Nanjing facility also OLAW-certified.
6
New R&D facilities have LEED Gold Certification.
7
Kind to Animals
-60
Legend Biotech conducts pre-clinical studies on animals to assess product safety, requiring a license for such experimentation.
1
This indicates compliance with legal mandates, but the policy does not prohibit testing where legally required. The company does not disclose the number of animals used in testing annually,
2
nor does it provide transparent reduction targets. The company's R&D investment was $266.6 million in 2024
3
and $383 million in 2023,
4
with a total of $1.9 billion since inception,
5
but there is no specific information on the percentage of this budget allocated to animal-free technologies.
No War, No Weapons
-20
Legend Biotech Corporation's core business is focused on developing and commercializing cell therapies for oncology, with no evidence of revenue derived from arms or defense contracts.
1
The company's external revenue breakdown for the six months ended June 30, 2025, shows 47.2% from life-science services and products, 47.0% from biologics development services, and 5.5% from industrial synthetic biology products, none of which are arms or defense-related.
2
The company joined the UN Global Compact in 2023, which indicates support for its principles, but there is no evidence of consistent implementation across divisions.
3
Legend Biotech has an ethics and compliance program, including a code of conduct and a compliance hotline, and has filed a California Declaration of Compliance, demonstrating 100% compliance with ethical standards in core business operations.
4
Planet-Friendly Business
-60
Legend Biotech reported total Scope 1 and 2 greenhouse gas emissions of approximately 12,714 tCO₂e for 2024 and 12,973.53 tCO₂e for 2023.
1
Scope 3 emissions are not reported.
2
The company's new Philadelphia R&D facility is designed for LEED v4 Gold certification, but no information is provided on the percentage of all facilities that are green certified.
3
Waste is diverted through recycling and waste-to-energy when feasible, with 9.8 tons of cardboard and 1.23 tons of commingled recycling reported for 2023, but a total waste generation figure or diversion rate is not provided.
4
The company does not disclose specific reduction targets, including SBTi-aligned targets, nor a net-zero target year.
5
There is no information on renewable energy usage, water use, capital expenditure alignment with EU taxonomy, lifecycle impact analysis, recycled to virgin material ratio, carbon offset quality, climate positive initiatives, supply chain climate transparency, biodiversity efforts, deforestation policy, environmental compliance violations, environmental impact assessments, TCFD alignment, climate scenario analysis, stranded assets transparency, water from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing.
6
Respect for Cultures & Communities
0
Legend Biotech's business model, focused on biotechnology research, development, and manufacturing, does not inherently involve activities that typically necessitate formal partnerships with indigenous or local community groups, nor does it commonly lead to cultural appropriation incidents or require specific cultural impact assessment protocols. The company has no reported cultural appropriation incidents and no evidence of formal partnerships with indigenous or local community groups or a cultural impact assessment protocol.
1
Safe & Smart Tech
0
No evidence available to assess Legend Biotech Corporation on Safe & Smart Tech.
Zero Waste & Sustainable Products
-20
Legend Biotech has implemented waste reduction initiatives including recycling programs and waste-to-energy utilization.
1
The company manages hazardous waste by disposing of it in accordance with local laws and regulations through a third-party vendor.
2